Vaccine News and Research

Latest Vaccine News and Research

Vical reports net loss of $8.5 million for first-quarter 2010

Vical Incorporated today reported financial results for the quarter ended March 31, 2010. Revenues were $1.5 million for the first quarter of 2010 compared with $2.3 million for the first quarter of 2009, reflecting lower revenues under the company's license agreement with AnGes MG, Inc. Operating expenses were $10.1 million for the first quarter of 2010 compared with $10.6 million for the first quarter of 2009.

6 May 2010

New research to improve effectiveness of nicotine vaccination for cigarette smokers

If Pradeep K. Garg, Ph.D., of Wake Forest University Baptist Medical Center figures out why some smokers are more addicted to nicotine than others, it could lead to more successful smoking cessation treatments.

6 May 2010

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

A prescription drug already approved to treat genital warts and skin cancer may have a new use in boosting the effectiveness of future vaccines for bacterial and viral diseases, such as hepatitis C and HIV (the AIDS virus). These findings appear in ACS' Molecular Pharmaceutics, a bi-monthly journal.

6 May 2010

Research reveals reason for ineffectiveness of antioxidants against cardiovascular disease

A new study by researchers at the Swedish medical university Karolinska Institutet shows that the immune defence's T cells can attack the "bad" LDL cholesterol and thereby cause an inflammation that leads to atherosclerosis. By producing a vaccine against the T cell receptors, the researchers have managed to inhibit the development of atherosclerosis in animals.

6 May 2010

CU-Boulder develops inhalable vaccine for measles prevention

A team of researchers led by the University of Colorado at Boulder believe a dry powder, inhalable vaccine developed for measles prevention and slated for human clinical trials later this year in India will lead to other inhalable, inexpensive vaccines for illnesses ranging from tuberculosis to cervical cancer.

6 May 2010

Cohera Medical reports top-line results from Tissuglu clinical trial

Cohera Medical, Inc.® today announced that top-line clinical study results demonstrate the safety and preliminary effectiveness of the company's lead surgical adhesive product, TissuGlu®.

6 May 2010

Intercell to acquire Cytos' platform technology for monoclonal antibody discovery

Intercell AG today announced that it has signed an agreement with Cytos Biotechnology Ltd. to acquire Cytos' platform technology for monoclonal antibody discovery. The technology is based on expression cloning of monoclonal antibodies from human B-cells and enables the identification of anti-infective antibodies to prevent and treat infectious diseases.

6 May 2010

Latest LLMDA technology available to detect viruses, bacteria

Law enforcement authorities seeking to detect bioterrorism attacks, doctors diagnosing diseases and regulatory agencies checking product safety may find a new ally in a Lawrence Livermore National Laboratory detection technology.

6 May 2010

Nausea in pregnant women can be a sign of flu: Researchers

Nausea in pregnant women tends to fade after the first three months, but during the second and third trimesters it can be a sign of flu, researchers at UT Southwestern Medical Center have found in a study of expectant women who sought medical care.

6 May 2010

Emergent Biosolutions reports decreased revenue in 2010 first quarter

Emergent BioSolutions Inc. announced today its financial results for the first quarter ended March 31, 2010. For the first quarter 2010, total revenues were $46.8 million as compared to $64.5 million in 2009, and net income was $2.5 million, or $0.08 per share, as compared to $11.1 million, or $0.37 per share, in 2009.

6 May 2010

GeoVax Labs reports net loss of $690,789 for first-quarter 2010

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced its financial results for the three months ended March 31, 2010.

6 May 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

CEL-SCI Corporation today provided an update on its planned Phase III clinical trial of its cancer immunotherapy drug candidate Multikine. The Company, together with its development partners Teva Pharmaceutical Industries and Orient Europharma, has already selected 40 of the planned 50 global medical centers where the Multikine Phase III study will be conducted.

6 May 2010

FDA approves Provenge for treating men with advanced prostate cancer

The US Food and Drug Administration has approved a new 'cancer vaccine' for treating men with advanced prostate cancer.

6 May 2010

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

Clinipace Worldwide, a global full-service clinical research organization (CRO), announced today that Vaccinogen, a biotechnology company with more than three decades experience researching how to combat cancer using the body's own immune system, has selected the company to manage a pivotal phase 3b confirmatory trial for OncoVAX in the treatment of Stage II Colon Cancer.

6 May 2010

New breakthrough: Seaweed for treatment of swine flu

In a groundbreaking new discovery a Tasmanian company has used seaweed as treatment for swine flu. The lab trials have been going on for the past nine months using the undaria seaweed (better know as wakame seaweed) harvested from waters at Triabunna, of Tasmania's East Coast.

5 May 2010

Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma

Boehringer Ingelheim and Micromet, Inc. announced today that they have entered into a collaboration agreement for the research, development and commercialization of a new BiTE antibody for the treatment of multiple myeloma.

5 May 2010

Older men who receive pneumococcal vaccine not less likely to have heart attack, stroke: JAMA

Men 45 years or older who received pneumococcal vaccine were not less likely to have a heart attack or stroke compared to men who did not receive the vaccine, according to a study in the May 5 issue of JAMA.

5 May 2010

Cryo-EM images shed light on virus structure, function

UCLA researchers report in the April 30 edition of the journal Cell that they have imaged a virus structure at a resolution high enough to effectively "see" atoms, the first published instance of imaging biological complexes at such a resolution.

5 May 2010

Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine

Vical Incorporated today announced the enrollment of the first subject in its Phase 1 trial of the company's Vaxfectin®-formulated plasmid DNA (pDNA) pandemic influenza vaccine. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center (NMRC).

5 May 2010

Archivel Farma to start phase II clinical trials of RUTI vaccine for Latent Tuberculosis

Archivel Farma, S.L. has announced that its breakthrough treatment for tuberculosis (TB) will shortly start phase II clinical trials. The treatment uses the company's unique combination of its novel therapeutic vaccine called RUTI® in conjunction with an antibiotic. This cuts treatment time from nine months to one month, which reduces side effects and healthcare costs, by preventing re-infection during the eradication process. The company expects commercial availability in 2015.

5 May 2010

Vaccine News and Research

Latest Vaccine News and Research

Vical reports net loss of $8.5 million for first-quarter 2010

New research to improve effectiveness of nicotine vaccination for cigarette smokers

Prescription drug may have new use in boosting effectiveness of vaccines for bacterial, viral diseases

Research reveals reason for ineffectiveness of antioxidants against cardiovascular disease

CU-Boulder develops inhalable vaccine for measles prevention

Cohera Medical reports top-line results from Tissuglu clinical trial

Intercell to acquire Cytos' platform technology for monoclonal antibody discovery

Latest LLMDA technology available to detect viruses, bacteria

Nausea in pregnant women can be a sign of flu: Researchers

Emergent Biosolutions reports decreased revenue in 2010 first quarter

GeoVax Labs reports net loss of $690,789 for first-quarter 2010

Update on CEL-SCI's Phase III clinical trial of Multikine

FDA approves Provenge for treating men with advanced prostate cancer

Vaccinogen chooses Clinipace Worldwide to manage pivotal phase 3b confirmatory trial for OncoVAX

New breakthrough: Seaweed for treatment of swine flu

Boehringer Ingelheim, Micromet enter collaboration for new BiTE antibody for multiple myeloma

Older men who receive pneumococcal vaccine not less likely to have heart attack, stroke: JAMA

Cryo-EM images shed light on virus structure, function

Vical commences enrollment in Phase 1 trial of Vaxfectin DNA pandemic influenza vaccine

Archivel Farma to start phase II clinical trials of RUTI vaccine for Latent Tuberculosis

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in